Milrinone During Living Donor Hepatectomy
Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hepatectomy
Intervention: milrinone (Drug); placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: Seoul National University Hospital
Summary
Maintaining a low central venous pressure during living donor hepatectomy is routine
practice. The investigators tried to test the hypothesis that using milrinone to maintain a
low central venous pressure (CVP) during is associated with a superior surgical field and
less blood loss.
Clinical Details
Official title: Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: condition of surgical field
Secondary outcome: the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively
Eligibility
Minimum age: 19 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Living liver donors
Exclusion Criteria:
- Donors with concurrent cardiac, pulmonary, and urologic disease
- Hepatectomy performed laparoscopically
Locations and Contacts
Seoul National University Hospital, Seoul 110-744, Korea, Republic of
Additional Information
Starting date: January 2008
Last updated: August 26, 2009
|